This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ramanna, H. Articles by Robles de Medina, E. O. Search for Related Content PubMed PubMed Citation Articles by Ramanna, H. Articles by Robles de Medina, E. O.

CLINICAL STUDY

Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation

Hemanth Ramanna, MD^a, Arif Elvan, MD^a, Fred H. M. Wittkampf, PhD^a, Jacques M. T. de Bakker, PhD, Richard N. W. Hauer, MD^a and Etienne O. Robles de Medina, MD, FACC^a

^a Heart-Lung Institute, University Medical Center, Utrecht, Netherlands
Interuniversity Cardiology Institute of The Netherlands, Utrecht, Netherlands. ?1

Manuscript received May 4, 2000; revised manuscript received November 22, 2000, accepted December 21, 2000.

Reprint requests and correspondence: Dr. Hemanth Ramanna, Heart-Lung Institute, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands

OBJECTIVES

The objective was to assess the effect of verapamil on atrial fibrillation (AF) cycle length and spatial dispersion of refractoriness in patients with chronic AF.

BACKGROUND

Previous studies have suggested that verapamil prevents acute remodeling by AF. The effects of verapamil in chronic AF are unknown.

METHODS

During electrophysiologic study in 15 patients with chronic AF (duration >1 year), 12 unipolar electrograms were recorded from right atrial free wall, right atrial appendage and coronary sinus, along with monophasic action potential recordings from the right atrial appendage. The mean fibrillatory interval at each atrial recording site was used as an index for local refractoriness. Dispersion of refractoriness was calculated as the standard deviation of all local mean fibrillatory intervals expressed as a percentage of the overall mean fibrillatory interval. After baseline measurements, verapamil (0.075 mg/kg intravenous in 10 min) was infused and the measurements were repeated.

RESULTS

After administration of verapamil, mean fibrillatory intervals shortened by a mean of 16.6 ± 3.3 ms (p < 0.001) at the right free wall, 15.0 ± 3.5 ms (p < 0.001) at the appendage and 17.1 ± 3.2 ms (p < 0.01) in the coronary sinus. Monophasic action potential duration decreased by 15.9 ± 4.0 ms (p < 0.01). Dispersion of refractoriness increased in all patients from 3.8 ± 0.8 to 5.1 ± 1.8 (p < 0.001). A strong correlation between mean fibrillatory intervals and action potential duration was found, both before and after verapamil.

CONCLUSIONS

Verapamil caused shortening of refractoriness and increase in spatial dispersion of refractoriness in patients with chronic AF. This implies that verapamil is not useful in reversing the remodeling process in these patients.

Abbreviations and Acronyms   AF = atrial fibrillation   APD90 = monophasic action potential duration   CS = coronary sinus

This article has been cited by other articles:

				Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]

				K. Kumagai, H. Nakashima, H. Urata, N. Gondo, K. Arakawa, and K. Saku Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2197 - 2204. [Abstract] [Full Text] [PDF]

				S. A. Hassan, H. Oral, C. Scharf, A. Chugh, F. Pelosi, B. P. Knight, S. A. Strickberger, and F. Morady Rate-dependent effect of verapamil on atrial refractoriness J. Am. Coll. Cardiol., February 5, 2003; 41(3): 446 - 451. [Abstract] [Full Text] [PDF]

				C. Sticherling, H. Tada, W. Hsu, A. C. Bares, H. Oral, F. Pelosi, B. P. Knight, S. A. Strickberger, and F. Morady Effects of Diltiazem and Esmolol on Cycle Length and Spontaneous Conversion of Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2002; 7(2): 81 - 88. [Abstract] [PDF]

				A. Shimizu and O. A. Centurion Electrophysiological properties of the human atrium in atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 302 - 314. [Abstract] [Full Text] [PDF]

				A. Goette, G. Juenemann, B. Peters, H. U. Klein, A. Roessner, C. Huth, and C. Rocken Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery Cardiovasc Res, May 1, 2002; 54(2): 390 - 396. [Abstract] [Full Text] [PDF]

				Y. Kurita, H. Mitamura, A. Shiroshita-Takeshita, A. Yamane, M. Ieda, O. Kinebuchi, T. Sato, S. Miyoshi, M. Hara, S. Takatsuki, et al. Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling Cardiovasc Res, May 1, 2002; 54(2): 447 - 455. [Abstract] [Full Text] [PDF]